Homatropine Eye Drops are used to produce mydriasis as in patients undergoing refractory surgery. It is also used in patients with uveitis.
Homatropine Eye Drops Uses:
-
Mydriasis and cycloplegia for refraction:
- It is used to produce mydriasis before and after surgery (producing cycloplegia and mydriasis for refraction).
-
Optical aid:
- It may be used as an optical aid in cases of axial lens opacities.
-
Uveitis:
- It is used to treat the inflammatory conditions of the uveal tract.
Homatropine Dose in Adults
Note: Patients with heavily pigmented irides may require higher doses.
Homatropine Dose in the treatment of Refraction:
- Ophthalmic: 2% or 5% solution:
- Instill 1 to 2 drops into the affected eye.
- The dose may be repeated in 5 to 10 minutes if necessary
Homatropine eye drops Dose in the treatment of Uveitis:
- Ophthalmic: 2% or 5% solution:
- Instill 1 to 2 drops into the affected eye every 3 to 4 hours or as advised by the physician.
Homatropine Dose in Cildrens
Note: Patients with heavily pigmented irides may require higher doses.
Homatropine dose in the treatment of Mydriasis and cycloplegia for refraction:
-
Infants ≥3 months, Children, and Adolescents:
- Ophthalmic: 5% solution:
- Instill 1 to 2 drops into the affected eye immediately before the procedure.
- The dose may be repeated once in 5 to 10 minutes if required.
- Ophthalmic: 5% solution:
Homatropine eye drops dose in the treatment of Uveitis:
-
Infants ≥3 months, Children, and Adolescents:
- Ophthalmic: 5% solution:
- Instill 1 to 2 drops into the affected eye every 3 to 4 hours or as advised by the healthcare expert.
- Ophthalmic: 5% solution:
Pregnancy Risk Factor C
- It has not yet been tested in human or animal pregnancies.
Use during breastfeeding:
- It is unknown if the drug is excreted into breastmilk. It is recommended that breastfeeding mothers avoid using the drug.
Dose in Kidney Disease:
There are no dosage adjustments provided in the manufacturer’s labeling.
Dose in Liver disease:
There are no dosage adjustments provided in the manufacturer’s labeling.
Side effects of Homatropine eye drops:
-
Cardiovascular:
- Edema
-
Central Nervous System:
- Burning Sensation
- Stinging Sensation
-
Dermatologic:
- Eczema
-
Endocrine & Metabolic:
- Increased Thirst
-
Gastrointestinal:
- Xerostomia
-
Local:
- Local Irritation
-
Ophthalmic:
- Blurred Vision
- Follicular Conjunctivitis
- Increased Intraocular Pressure
- Ocular Exudate
- Photophobia
- Vascular Congestion Of The Eye
Contraindications to Homatropine eye drops:
- Patients who have had glaucoma in the past or are at high risk for developing it (such as those with narrow anterior rooms).
- Allergy reactions to any component of the drug or the drug itself
- Cross-reactivity to belladonna alkaloids may occur because of the similarities in structure, however, data is limited.
Warnings and precautions
-
CNS effects
- Neurological symptoms may include confusion, delirium and agitation. Excessive use of medicine can cause neurologic symptoms.
- Although neurological symptoms can occur in any age group, they are more common in children and the elderly.
- Patients who are required to be alert for tasks such as driving heavy machinery or operating heavy machinery should not take this drug.
-
Ocular light sensitivity:
- To avoid ocular hypersensitivity, patients should be taught to use sunglasses and appropriate eye protection after applying the eye drops.
-
Down syndrome
- Angle-closure Glaucoma should be checked in patients with Down syndrome before they use the eye drops. These patients are more likely to develop angle-closure.
-
Keratoconus
- Patients with Keratoconus should use it with caution as fixed pupillary dilation could occur.
Homatropine: Drug Interaction
|
Risk Factor C (Monitor therapy) |
|
|
Acetylcholinesterase Inhibitors |
May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. |
|
Amantadine |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Anticholinergic Agents |
May enhance the adverse/toxic effect of other Anticholinergic Agents. |
|
Botulinum Toxin-Containing Products |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Cannabinoid-Containing Products |
Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Exceptions: Cannabidiol. |
|
Chloral Betaine |
May enhance the adverse/toxic effect of Anticholinergic Agents. |
|
Gastrointestinal Agents (Prokinetic) |
Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). |
|
Glucagon |
Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. |
|
Itopride |
Anticholinergic Agents may diminish the therapeutic effect of Itopride. |
|
Mianserin |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Mirabegron |
Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. |
|
Nitroglycerin |
Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. |
|
Opioid Agonists |
Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. |
|
Ramosetron |
Anticholinergic Agents may enhance the constipating effect of Ramosetron. |
|
Thiazide and Thiazide-Like Diuretics |
Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. |
|
Topiramate |
Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. |
|
Risk Factor D (Consider therapy modification) |
|
|
Pramlintide |
May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. |
|
Secretin |
Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. |
|
Risk Factor X (Avoid combination) |
|
|
Aclidinium |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Cimetropium |
Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. |
|
Eluxadoline |
Anticholinergic Agents may enhance the constipating effect of Eluxadoline. |
|
Glycopyrrolate (Oral Inhalation) |
Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). |
|
Glycopyrronium (Topical) |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Ipratropium (Oral Inhalation) |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Levosulpiride |
Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. |
|
Oxatomide |
May enhance the anticholinergic effect of Anticholinergic Agents. |
|
Potassium Chloride |
Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. |
|
Potassium Citrate |
Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. |
|
Revefenacin |
Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. |
|
Tiotropium |
Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. |
|
Umeclidinium |
May enhance the anticholinergic effect of Anticholinergic Agents. |
Monitoring Parameters:
None mentioned. Monitor the response to treatment.
How to administer Homatropine eye drops?
Ophthalmic instillation:
- Wash hands when instilling the eye drops and remove contact lenses. Avoid touching the tip of the applicator to the surrounding skin, eyelashes, or other ocular structures.
- To reduce the chances of systemic absorption, press the lacrimal sac for 1 - 3 minutes after instilling the eye drops.
- Contact lenses can be worn after 10 to 15 minutes. If the eyes are red or inflamed, avoid wearing contact lenses.
Mechanism of action of Homatropine:
- It dilates pupils (mydriasis), and causes cycloplegic (loss of or paralysis) of accommodation.
- It inhibits the response of the ocular muscles to cholinergic stimulation (iris sphincter muscle and muscles of the ciliary organ).
International Brand Names of Homatropine eye drops:
- Homatropaire
- Isopto Homatropine
- Bernardtropina
- Bromhydrate d'homatropine-Chauvin
- Hemasol
- Hemomin
- Homapin
- Homarin Forte
- Homatogen
- Homatropin
- HomatropinPOS
- Homatropina
- Homatropine
- Homatropine Faure
- Homo Grin
- Isopto Homatropine
- Isopto-Homatropine
- Matropin
- Minims Homatropine
- Minims Homatropine Hydrobromide
- Minims-Homatropinhydrobromid
- Ocuhomapine
- Omatropina
- Paratropina
Homatropine Brand Names in Pakistan:
Homatropine (HBr) Eye Drops 2 %w/v in Pakistan |
|
| Homatropine | Ethical Laboratories (Pvt) Ltd. |